文献速递肝病消化道肿瘤与早癌

美国慢性丙型肝炎患者躯干肥胖和糖尿病患病率高于中国患者,可能促进更快速进展为晚期肝病

The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-08-22

多因素分析显示美国研究地点、年龄较大、躯干肥胖、糖尿病和既往HCV治疗是晚期疾病的显著预测因素。作者推测潜在脂肪肝病可能是差异的主要贡献因素,糖代谢异常管理应与抗病毒治疗同时进行。

要点

  • 美国HCV患者肝硬化(38.2% vs 16.0%)和HCC(14.1% vs 2.7%)比例显著高于中国患者。
  • 美国患者更常见男性(61.4% vs 48.5%)、肥胖(38.4% vs 16.8%)和糖尿病(21.8% vs 10.8%)。
  • 按感染时长分层后美国患者仍更可能有晚期疾病,躯干肥胖和糖尿病是显著预测因素。

核心结论

  • 美国HCV患者比中国患者有更晚期的肝病。
  • 作者推测潜在脂肪肝病可能是该差异的主要贡献因素。
  • 作者认为糖代谢异常的管理应与抗病毒治疗同时进行以获得最佳结局。

研究设计与样本

  • 前瞻性研究,比较美国1个研究地点和中国3个研究地点招募的2个HCV患者队列。
  • 使用标准化问卷收集危险因素和病史,肝硬化和HCC诊断基于预先定义的标准。

主要发现

  • 美国患者更可能为男性(61.4% vs 48.5%)、年龄更大(中位年龄57 vs 53岁)、肥胖(38.4% vs 16.8%)和患糖尿病(21.8% vs 10.8%)。
  • 美国患者肝硬化比例显著更高(38.2% vs 16.0%),HCC比例也显著更高(14.1% vs 2.7%)。
  • 研究者估计美国患者感染时间比中国患者早10年,但按感染时长分层后美国患者仍更可能有晚期疾病。
  • 多因素分析中,美国研究地点、年龄较大、躯干肥胖、糖尿病和既往HCV治疗是晚期疾病的显著预测因素。

临床怎么用

  • 作者认为糖代谢异常的管理应与抗病毒治疗同时进行以获得最佳结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic hepatitis C virus (HCV) infection is the leading cause of cirrhosis and hepatocellular carcinoma (HCC) in the United States (US) and an emerging cause in China. AIM: To compare the clinical characteristics of hepatitis C patients in the US and China, and factors influencing disease stage. METHODS: Prospective study of 2 cohorts of HCV patients recruited at 1 site in the US and 3 sites in China. Standardised questionnaire on risk factors and medical history were used and diagnosis of cirrhosis and HCC was based on pre-defined criteria. RESULTS: One thousand nine hundred and fifty seven patients (1000 US and 957 China) were enrolled. US patients were more likely to be men (61.4% vs 48.5%), older (median age 57 vs 53 years), obese (38.4% vs 16.8%) and diabetic (21.8% vs 10.8%). A significantly higher per cent of US patients had cirrhosis (38.2% vs 16.0%) and HCC (14.1% vs 2.7%). Investigator estimated time at infection in US was 10 years earlier than in Chinese patients but US patients were more likely to have advanced disease even after stratifying for duration of infection. Study site in the US, older age, truncal obesity, diabetes and prior HCV treatment were significant predictors of advanced disease on multivariate analysis. CONCLUSIONS: HCV patients in the US had more advanced liver disease than those in China. We speculate that underlying fatty liver disease may be a major contributor to this difference, and management of glycometabolic abnormalities should occur in parallel with anti-viral therapy to achieve optimal outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rao H, Wu E, Fu S, et al. The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. Aliment Pharmacol Ther. 2017. PMID: 28833342. doi:10.1111/apt.14273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。